HGH 191AA

Also known as · Somatropin · rhGH · Genotropin · Norditropin · Humatrope

01 / Dosing schedule

Cited dosing

The FDA-approved adult GHD schedule offers two approaches: a non-weight-based starting dose of ~0.2 mg/day (range 0.15–0.30 mg/day) titrated by IGF-1 response, or a weight-based initial dose not more than 0.04 mg/kg/week.

Genotropin — adult GHD, non-weight-based

PhaseDose & frequency
Starting dose~0.2 mg/day subQ (range 0.15–0.30 mg/day)
TitrationIncrease by 0.1–0.2 mg/day every 1–2 months
Guided byClinical response + age/gender-adjusted IGF-1
FrequencyOnce daily (6–7 injections per week)

Source · FDA label — Genotropin (2014) ↗

Genotropin — adult GHD, weight-based

PhaseDose & frequency
Starting doseNot more than 0.04 mg/kg/week subQ
TitrationIncrease to ≤0.08 mg/kg/week at 4–8 week intervals
Divided across6–7 subQ injections per week

Source · FDA label — Genotropin (2014) ↗

Source indication · Adult growth hormone deficiency (Genotropin label).

Injection frequency
Once daily, 6–7 injections per week.
Injection sites
Abdomen, thigh, or upper arm. Rotate sites to reduce lipoatrophy.

02 / Reconstitution

Reconstitution reference

Research-grade somatropin ships as a lyophilized vial with a supplied diluent. A typical prep is a 10 IU (~3.33 mg) vial with 1 mL bacteriostatic water = 10 IU/mL. At that concentration, a 2 IU dose is 0.2 mL = 20 units on a U‑100 syringe.

Vial10 IU (~3.33 mg)
BAC water1 mL
Concentration10 IU/mL
Example dose2 IU
On a U‑100 syringe20 units on U‑100
Open the reconstitution calculator →

03 / Overview

Protocol overview

Somatropin is recombinant human growth hormone (191 amino acid sequence, identical to pituitary GH). It acts directly on GH receptors and drives IGF-1 production in the liver and peripheral tissues.

Adult GHD dosing is orders of magnitude lower than pediatric or bodybuilding-culture doses. The label starts at 0.15–0.30 mg/day (roughly 0.5–1 IU) and titrates by IGF-1, not by feel.

The FDA label emphasizes that maintenance doses vary considerably by patient and gender — women generally require higher doses than men.

Adverse effects at supraphysiologic doses (edema, arthralgia, carpal tunnel, insulin resistance) scale with the dose. The label's slow titration is the primary tool for staying below that threshold.

04 / References

References

  1. FDA prescribing information — Genotropin (somatropin) 2014 ↗
  2. Molitch ME et al. Evaluation and Treatment of Adult Growth Hormone Deficiency: Endocrine Society Guideline. JCEM 2011 ↗